Sign in
Taking people in PolandPhase 3

Low-dose prednisone added to standard therapy for heart involvement in Fabry disease

Tests prednisone added to standard treatment in adults with Fabry disease affecting the heart.

Key facts

Who runs it
Medical University Of Lodz
Where
Katowice and Lodz, PolandSee the 2 sites
Registry title
Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease
Status
Recruiting
Phase
Phase 3
People taking part
40 people, planned
Started
5 Mar 2026
Expected to end
31 Aug 2030
Type of study
Interventional
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Fabry disease who already get enzyme replacement therapy or migalastat and who have signs of heart involvement. It tests low dose prednisone added to that treatment.

Age
18 years or older
Sex
All sexes
Disease stage
Fabry disease with heart involvement: at least one abnormal finding on ECG, heart ultrasound or heart MRI, and troponin T above 14 ng/l
Earlier treatment
Must be on enzyme replacement therapy (agalsidase alfa or agalsidase beta) or chaperone therapy with migalastat. Must not have taken variable-dose corticosteroids for other reasons less than 3 months before joining.
Biomarker or test result
High-sensitivity troponin T level above 14 ng/l

Main reasons for not taking part

  • Pregnancy or breastfeeding
  • eGFR below 30 ml/m2/min
  • Diabetes
  • Cataracts
  • Stomach or duodenal ulcer, or gastrointestinal bleeding in the past 12 months

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Giving informed consent
  • Age at least 18 years on the day of the screening visit
  • Ongoing treatment for Fabry disease: Enzyme replacement therapy with agalsidase alfa or agalsidase beta, or Chaperone therapy with migalastat
  • Cardiac involvement in Fabry disease (meeting at least one of the following criteria a-c): a. electrocardiographic abnormalities defined as: - short PR (less than 120 ms) or - long PR (200 ms or more) or - bradycardia (heart rate less than <60 beats per minute) or - chronotropic failure or - repolarization abnormalities. b. echocardiographic abnormalities defined as: - left ventricular hypertrophy (wall thickness of 12 mm or more), or - reduced global longitudinal strain (GLS<-16%), or - dilatation of the aortic annulus >22 mm/m2, or - thickening of the mitral and aortic valve leaflets (>5 mm and 2 mm, respectively) with at least mild valvular regurgitation. c. cardiac MRI abnormalities defined as: - left ventricular hypertrophy defined as LVMI>2SD above the mean based on age- and gender-specific reference ranges, or - papillary muscle hypertrophy, or - the presence of late gadolinium enhancement (LGE)
  • High-sensitivity troponin T level above >14 ng/l
  • Contraceptive readiness (for women)

Who cannot take part

  • Concomitant treatment with variable-dose corticosteroids for other indications less than 3 months prior to study inclusion
  • Planned attenuated vaccine
  • Episode of gastrointestinal bleeding within 12 months prior to starting treatment
  • Patient not treated with enzyme replacement therapy or chaperone therapy
  • Hypersensitivity to any component of the test drug compound
  • Diagnosis of mental illness
  • Diabetes
  • Peptic ulcer disease of the stomach and/or duodenum
  • Chronic and/or systemic fungal infection
  • Coexistence with autoimmune disease
  • eGFR<30ml/m2/min
  • Age < 18 years at the time of screening
  • Reluctance to adhere to a scheduled schedule of visits
  • Pregnancy (for women)
  • Lactation (for women)
  • Cataracts
  • Inability to give informed consent to participate in the study

Where in Poland

  • Gornoslaskie Centrum Medyczne Im Prof. Leszka Gieca Sląskiego Uniwersytetu Medycznego W KatowicachKatowice, PolandTaking people
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Kliniczny Uniwersytetu Medycznego W LodziLodz, PolandTaking people

About the trial

What the trial wants to find out

The main objective of the study is to evaluate whether the use of prednisone - as an adjunctive treatment to standard therapy (ERT or CHT) - can effectively improve cardiac function by reducing myocardial inflammation, considered one of the key pathological mechanisms in Fabry cardiomyopathy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease – prospective randomized controlled phase III trial
Plain-language title
Low-dose prednisone added to standard therapy for heart involvement in Fabry diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
4 November 2026